Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial
| Autor: | Bharucha, KN, Brunner, HI, Penades, IC, Nikishina, I, Rubio-Perez, N, Oliveira, S, Kobusinska, K, Schmeling, H, Sztajnbok, F, Weller-Heinemann, F, Zholobova, E, Zulian, F, Allen, R, Chaitow, J, Frane, J, Wells, C, Ruperto, N, De Benedetti, F, Paediat Rheumatol Int Trials Org, Pediat Rheumatology Collaborative |
|---|---|
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | JOURNAL OF RHEUMATOLOGY r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname |
| ISSN: | 0315-162X |
| Popis: | Objective. Evaluate growth in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with tocilizumab (TCZ) for up to 2 years in a phase III trial. Methods. Patients with pcJIA lasting at least 6 months and inadequate response to methotrexate received open-label TCZ intravenously every 4 weeks (randomly assigned to 8 or 10 mg/kg if they weighed = 30 kg) for 16 weeks. Patients with JIA American College of Rheumatology 30 response at Week 16 were randomly assigned to TCZ or placebo for 24 weeks, with an open-label extension through Week 104. Mean +/- SD height velocity (cm/yr) and World Health Organization (WHO) height SD score (SDS) were measured in patients receiving >= 1 dose of TCZ who did not receive growth hormone and in patients whose baseline Tanner stage was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|